AI data company Tempus AI announced it will acquire cancer genomics company Personalis in a transaction valued at approximately $1.5 billion. The acquisition will integrate Personalis' molecular ...

July 20 (Reuters) - Tempus AI (TEM.O), opens new tab said on Monday it would buy Personalis (PSNL.O), opens new tab in a deal valued at about $1.5 billion, ‌adding a cancer test to the AI-enabled ...

July 20 (Reuters) - Tempus AI said on Monday it would buy Personalis in a deal valued at about $1.5 billion, adding a cancer test to the AI-enabled precision medicine firm's oncology portfolio.

Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology. Tempus, which is putting a total enterprise value of $1.5 billion on ...

Tempus AI now offers an attractive risk-reward setup, with valuations normalized to ~5.7x forward revenue and improved visibility on durable, high-margin revenues. Organic growth remains robust at ~25 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Analysts: slightly positive, with targeted durability and visibility questions such as "longevity and extension potential" (Morgan Stanley) and cadence to "hit $65 million" EBITDA (JPMorgan).

Debuting at SXSW, the comedy follows a young woman who, in the wake of a devastating break-up, becomes increasingly fixated on her ex-boyfriend's ex-girlfriend. By Angie Han Television Critic There ...

Yesterday investors watched to see whether Tempus AI’s full-year and Q4 2025 results would validate the profitability story that the January pre-announcement left unfinished. The complete financials ...

Tempus announced its Pan-Cancer HRD-RNA algorithm today, an AI-driven tool that identifies Homologous Recombination Deficiency using RNA analysis rather than traditional DNA tests. This approach ...